Business
The vaccine and public health debate at the center of CDC upheaval, explained
The exterior of the Center for Disease Control and Prevention (CDC) main campus in Atlanta, Georgia, U.S., Aug. 27, 2025.
Alyssa Pointer | Reuters
The Centers for Disease Control and Prevention is facing a leadership upheaval — and at the center of the shakeup is concern about the agency’s approach to vaccines and U.S. public health.
The White House on Thursday said President Donald Trump had fired CDC Director Susan Monarez after she refused to resign. Lawyers for Monarez said she was “targeted” for “protecting the public over serving a political agenda.”
Meanwhile, four other top health officials at the CDC announced Wednesday they were quitting the agency. That includes Demetre Daskalakis, director of the National Center for Immunization and Respiratory Diseases, who said he could no longer serve because of the “weaponizing of public health.”
Former Centers for Disease Control and Prevention (CDC) Chief Medical Officer Debra Houry, former National Center for Immunization and Respiratory Diseases Director Demetre Daskalakis, and former National Center for Emerging and Zoonotic Infectious Diseases Director Daniel Jernigan hold flowers and react after they appeared during a protest, a day after the White House fired CDC director Susan Monarez and several top officials resigned, in Atlanta, Georgia, U.S., Aug. 28, 2025.
Alyssa Pointer | Reuters
The loss of those respected leaders and efforts to oust Monarez follow a string of measures by Health and Human Services Secretary Robert F. Kennedy Jr. – a prominent vaccine skeptic – to overhaul federal health agencies and change immunization policy in the U.S. That includes mass firings, gutting a key government vaccine panel, canceling studies on mRNA shot technology and hiring those with like-minded views.
Kennedy has a long track record of making misleading and false statements about the safety of vaccine shots, but in his current role, he wields enormous power over the agencies that regulate the immunizations and determine both who can get them and which ones insurance plans should cover.
Dr. Georges Benjamin, executive director of the American Public Health Association, said the leadership overhaul at the CDC represents Kennedy’s “failed leadership and reckless mismanagement,” adding that he has a “blatant disregard for science and evidence-based public health.”
The agency is also reeling from funding cuts and an Aug. 8 attack by a gunman at its headquarters in Atlanta.
Some health policy experts said the leadership exodus could further erode the public’s trust in an agency that is responsible for detecting disease outbreaks and guiding state and local health departments when needed.
“This has to be seen on top of a raft of ways that CDC has been weakened and undermined, maybe irreversibly,” Lawrence Gostin, professor of public health law at Georgetown University, told CNBC.
“Throughout all of those years, CDC has been independent and the jewel in the crown of American science. That’s literally all crumbling as we speak,” he said. “This is almost the definition of politics undermining science.”
Top official highlights vaccine concerns
Daskalakis was among the officials to explicitly highlight concerns with the views held by Kennedy and his staff, which he said challenged his ability to continue in his role at the agency.
“I am unable to serve in an environment that treats CDC as a tool to generate policies and materials that do not reflect scientific reality and are designed to hurt rather than to improve the public’s health,” Daskalakis said in his resignation letter, which was posted on X.
He said the CDC’s recent changes to the adult and children’s immunization schedule “threaten the lives of the youngest Americans and pregnant people.”
High-ranking members of the Centers for Disease Control and Prevention (CDC), dressed in uniform, salute former CDC Chief Medical Officer Debra Houry, former National Center for Immunization and Respiratory Diseases Director Demetre Daskalakis, and former National Center for Emerging and Zoonotic Infectious Diseases Director Daniel Jernigan, a day after the White House fired CDC Director Susan Monarez and several top officials resigned, in Atlanta, Georgia, U.S., Aug. 28, 2025.
Alyssa Pointer | Reuters
In May, Kennedy said the CDC removed Covid vaccines from the list of shots recommended for healthy pregnant women and children. An updated guidance days later said shots “may” be given to those groups.
Daskalakis said the data analyses that supported the change have “never been shared with the CDC despite my respectful requests to HHS and other leadership.” He also said HHS circulated a “frequently asked questions” document written to support Kennedy’s decision without input from CDC subject matter experts, and that it cited studies “that did not support the conclusions that were attributed to these authors.”
On Wednesday, the Food and Drug Administration approved the latest round of Covid vaccines only for those at higher risk of serious illness, marking another shift in policy around those shots since the pandemic began.
Shares of Covid vaccine makers dipped on Thursday. Moderna’s stock fell more than 3%, while shares of Pfizer fell around 2%.
Those companies and other drugmakers have been bracing for changes to vaccine and public health policy since Trump first named Kennedy as his pick to lead HHS in November. The CDC’s leadership shakeup only adds to the uncertainty in the pharmaceutical industry, which is also grappling with Trump’s drug pricing policies.
Kennedy tried to distance himself from his previous views about vaccines and other health policies during his Senate confirmation hearings back in January, claiming that he isn’t “anti-vaccine” and would not make it “difficult or discourage people from taking” routine shots for measles and polio.
But some of Kennedy’s recent efforts appear to reflect his vaccine-critical views. For example, Kennedy in August argued that mRNA vaccines – the technology used in Covid shots – are ineffective and advocated for the development of other jabs that use other “safer” platforms.
Years of research support the effectiveness of mRNA Covid vaccines, and the technology is now approved for use in shots against respiratory syncytial virus.
Threat to public health
Former National Center for Immunization and Respiratory Diseases Director Demetre Daskalakis, next to former National Center for Emerging and Zoonotic Infectious Diseases Director Daniel Jernigan, speaks to the media during a protest, a day after the White House fired CDC director Susan Monarez and several top officials resigned, in Atlanta, Georgia, U.S., Aug. 28, 2025.
Alyssa Pointer | Reuters
As changes roll through the CDC, concerns over a threat to public health and protocol are growing.
Daskalakis slammed the means by which HHS and other CDC leadership have communicated major policy changes. For example, Kennedy announced he was firing the entirety of the Advisory Committee on Immunization Practices – a panel of vaccine advisors to the CDC – through an X post and op-ed “rather than direct communication with these valuable experts,” Daskalakis said.
He said he believed there would be an opportunity to brief Kennedy on key topics such as measles, avian influenza and the approach to the respiratory virus season. But Daskalakis said seven months into the new administration, no CDC subject matter expert from his center had briefed Kennedy.
“I am not sure who the Secretary is listening to, but it is quite certainly not to us,” he said. “Unvetted and conflicted outside organizations seem to be the sources HHS use over the gold standard science of CDC and other reputable sources.”
Former Centers for Disease Control and Prevention (CDC) Chief Medical Officer Debra Houry, followed by former National Center for Immunization and Respiratory Diseases Director Demetre Daskalakis, and former National Center for Emerging and Zoonotic Infectious Diseases Director Daniel Jernigan, reacts during a protest, a day after the White House fired CDC director Susan Monarez and several top officials resigned, in Atlanta, Georgia, U.S., Aug. 28, 2025.
Alyssa Pointer | Reuters
Dr. Debra Houry, who also resigned Wednesday from her post as the CDC’s chief medical officer, similarly said that senior leaders “never were able to brief the Secretary” on any of the issues the agency deals with.
“The CDC scientists are top notch and excellent,” she told MSNBC in an interview. “What we would actually have preferred was to have more interactions with the secretary.”
Houry added that “over the past few months, things at the CDC have been really difficult when it comes to having science and data driven decisions.”
As longtime experts leave the CDC, the threat of infectious diseases is growing. While measles cases are ticking up in the U.S. again, bird flu is spreading in cattle. The first human case of the flesh-eating parasite “New World screwworm” has been detected in the country.
The departures could “make our public health less assured,” Benjamin of the American Public Health Association said.
Susan Monarez, U.S. President Donald Trump’s nominee to be director of the Centers for Disease Control and Prevention, testifies before a Senate Health, Education, Labor, and Pensions Committee confirmation hearing on Capitol Hill in Washington, D.C., U.S., June 25, 2025.
Kevin Mohatt | Reuters
He said the leadership disruption also raises concerns about the nation’s ability to detect and respond to an emerging infectious disease spreading because the CDC is the “glue that holds” individual doctors and state and local health departments together.
“I am worried that we won’t know in time, and that we’ll be chasing that disease for far longer than we should,” Benjamin said.
Benjamin said he has “little confidence” that the Trump administration will find someone “highly competent” with relevant experience to replace Monarez.
“It obviously all has enormous implications for the health and well being of the public, and enormous implications around the finances of our nation,” he said. “Prevention and wellness saves us money, and public health is the best buy.”
Business
Private sector data: Over 2 lakh private companies closed in 5 years; govt flags monitoring for suspicious cases – The Times of India
NEW DELHI: The government on Monday said that over the past five years, more than two lakh private companies have been closed in India.According to data provided by Minister of State for Corporate Affairs Harsh Malhotra in a written reply to the Lok Sabha, a total of 2,04,268 private companies were shut down between 2020-21 and 2024-25 due to amalgamation, conversion, dissolution or being struck off from official records under the Companies Act, 2013.Regarding the rehabilitation of employees from these closed companies, the minister said there is currently no proposal before the government, as reported by PTI. In the same period, 1,85,350 companies were officially removed from government records, including 8,648 entities struck off till July 16 this fiscal year. Companies can be removed from records if they are inactive for long periods or voluntarily after fulfilling regulatory requirements.On queries about shell companies and their potential use in money laundering, Malhotra highlighted that the term “shell company” is not defined under the Companies Act, 2013. However, he added that whenever suspicious instances are reported, they are shared with other government agencies such as the Enforcement Directorate and the Income Tax Department for monitoring.A major push to remove inactive companies took place in 2022-23, when 82,125 companies were struck off during a strike-off drive by the corporate affairs ministry.The minister also highlighted the government’s broader policy to simplify and rationalize the tax system. “It is the stated policy of the government to gradually phase out exemptions and deductions while rationalising tax rates to create a simple, transparent, and equitable tax regime,” he said. He added that several reforms have been undertaken to promote investment and ease of doing business, including substantial reductions in corporate tax rates for existing and new domestic companies.
Business
Pakistan’s Textile Exports Reach Historic High in FY2025-26 – SUCH TV
Pakistan’s textile exports surged to $6.4 billion during the first four months of the 2025-26 fiscal year, marking the highest trade volume for the sector in this period.
According to the Pakistan Bureau of Statistics (PBS), value-added textile sectors were key contributors to the growth.
Knitwear exports reached $1.9 billion, while ready-made garments contributed $1.4 billion.
Significant increases were observed across several commodities: cotton yarn exports rose 7.74% to $238.9 million, and raw cotton exports jumped 100%, reaching $2.6 million from zero exports the previous year.
Other notable gains included tents, canvas, and tarpaulins, up 32.34% to $53.48 million, while ready-made garments increased 5.11% to $1.43 billion.
Exports of made-up textile articles, excluding towels and bedwear, rose 4.17%, totaling $274.75 million.
The report also mentioned that the growth in textile exports is a result of improved global demand and stability in the value of the Pakistani rupee.
Business
Peel Hunt cheers ‘positive steps’ in Budget to boost London market and investing
UK investment bank Peel Hunt has given some support to under-pressure Chancellor Rachel Reeves over last week’s Budget as it said efforts to boost the London market and invest in UK companies were “positive steps”.
Peel Hunt welcomed moves announced in the Budget, such as the stamp duty exemption for shares bought in newly listed firms on the London market and changes to Isa investing.
It comes as Ms Reeves has been forced to defend herself against claims she misled voters by talking up the scale of the fiscal challenge in the run-up to last week’s Budget, in which she announced £26 billion worth of tax rises.
Peel Hunt said: “Following a prolonged period of pre-Budget speculation, businesses and investors now have greater clarity from which they can start to plan.
“The key measures were generally well received by markets, particularly the creation of additional headroom against the Chancellor’s fiscal rules.
“Initiatives such as a stamp duty holiday on initial public offerings (IPOs) and adjustments to the Isa framework are intended to support UK capital markets and encourage investment in British companies.
“These developments, alongside the Entrepreneurship in the UK paper published simultaneously, represent positive steps toward enhancing the UK’s attractiveness for growth businesses and long-term investors.”
Ms Reeves last week announced a three-year stamp duty holiday on shares bought in new UK flotations as part of a raft of measures to boost investment in UK shares.
She also unveiled a change to the individual savings account (Isa) limit that lowers the cash element to £12,000 with the remaining £8,000 now redirected into stocks and shares.
But the Chancellor also revealed an unexpected increase in dividend tax, rising by 2% for basic and higher rate taxpayers next year, which experts have warned “undermines the drive to increase investing in Britain”.
Peel Hunt said the London IPO market had begun to revive in the autumn, although listings activity remained low during its first half to the end of September.
Firms that have listed in London over recent months include The Beauty Tech Group, small business lender Shawbrook and tinned tuna firm Princes.
Peel Hunt added that deal activity had “continued at pace” throughout its first half, with 60 transactions announced across the market during that time and 10 active bids for FTSE 350 companies, as at the end of September.
Half-year results for Peel Hunt showed pre-tax profits jumped to £11.5 million in the six months to September 30, up from £1.2 million a year earlier, as revenues lifted 38.3%.
Peel Hunt said its workforce has been cut by nearly 10% since the end of March under an ongoing savings drive, with full-year underlying fixed costs down by around £5 million.
Steven Fine, chief executive of Peel Hunt, said: “The second half has started strongly, with the group continuing to play leading roles across both mergers and acquisitions and equity capital markets mandates.”
-
Sports1 week agoWATCH: Ronaldo scores spectacular bicycle kick
-
Entertainment1 week agoWelcome to Derry’ episode 5 delivers shocking twist
-
Politics1 week agoWashington and Kyiv Stress Any Peace Deal Must Fully Respect Ukraine’s Sovereignty
-
Business1 week agoKey economic data and trends that will shape Rachel Reeves’ Budget
-
Tech6 days agoWake Up—the Best Black Friday Mattress Sales Are Here
-
Politics1 week ago53,000 Sikhs vote in Ottawa Khalistan Referendum amid Carney-Modi trade talks scrutiny
-
Fashion1 week agoCanada’s Lululemon unveils team Canada kit for Milano Cortina 2026
-
Tech23 hours agoGet Your Steps In From Your Home Office With This Walking Pad—On Sale This Week
